We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AZN Astrazeneca Plc

52.00 (0.48%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  52.00 0.48% 10,914.00 10,918.00 10,922.00 11,018.00 10,858.00 10,946.00 2,417,068 16:35:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 28.43 169.28B
Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 10,862p. Over the last year, Astrazeneca shares have traded in a share price range of 9,461.00p to 12,390.00p.

Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £169.28 billion. Astrazeneca has a price to earnings ratio (PE ratio) of 28.43.

Astrazeneca Share Discussion Threads

Showing 5726 to 5748 of 6150 messages
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older
Going to add here, I see Baillie Gifford have bought big here recently..
Deutsche Bank raises AstraZeneca price target to 12,000 (11,500) pence - 'buy'
ShoreCap stays at 'buy' on AstraZeneca, sees further upgrades ahead on product pipeline

Analysts at ShoreCap reiterated their 'buy' recommendation for shares of drugs giant AstraZeneca, describing its second quarter top-line growth of 37% year-on-year at constant exchange rates "impressive".

"AZN have delivered a strong second quarter, with Q2 benefitting from a full quarter of Alexion integration and several products beating consensus expectations," analyst Dr.Susie Jana said in a research note sent to clients.

"Oncology was in line overall due to strong commercial execution and lower COVID-19 related headwinds than anticipated."

The analyst also called attention to the fact that AstraZeneca was reinvesting its strong revenues into research and development.

And there was more yet to come.

"AZN has a strong mid to late-stage pipeline, we expect product and candidate related news flow in 2023 to lead to further upgrades. A strong set of results underpinning the long-term growth story," she added.

"AZN shares trade on a FY23F PER of 16.8x, a c 5% premium versus US and European peers (mean 16.1x), which we believe is warranted based on its industry-leading earnings growth and pipeline prospects."

Are they different to any other company if the truth be known?. A fantastic company with enormous growth potential.
singing the blues
AstraZeneca PLC on Friday reported a swing to second-quarter net loss after booking a large foreign-exchange charge in its accounts, but raised its full-year revenue guidance due to better-than-expected Covid-19 medicine revenue.

The Anglo-Swedish pharma giant said it now expects to report a low twenties percentage rise in total revenue for the year, up from previous guidance of high teens percentage. It also said revenue from Covid-19 medicines are expected to be flat compared with 2021. It had previously guided for a low-to-mid twenties percentage fall.

AstraZeneca posted a net loss of $372 million for the quarter compared with a profit of $1.19 billion for the same period a year earlier.

Revenue for the quarter rose to $10.77 billion, from $8.22 billion. Revenue consensus was $10.45 billion.

Core earnings per share--one of the company's preferred metrics--rose to $1.72 in the quarter, compared with $0.90 and a consensus of $1.57.

Consensus figures have been taken from FactSet and are based on 16 analysts' projections.

AstraZeneca reiterated that it expects core EPS growth in the mid-to-high twenties percentage.

The board has increased its interim dividend to $0.93 a share compared with $0.90 for the first half of 2021.

Write to Ian Walker at

(END) Dow Jones Newswires

July 29, 2022 02:54 ET (06:54 GMT)

Pascal Soriot, Chief Executive Officer, AstraZeneca, said:

"AstraZeneca had a strong financial first half of 2022, and great pipeline delivery. We announced practice-changing data for several medicines including Enhertu in breast cancer, Farxiga in heart failure and Ultomiris in neuromyelitis optica spectrum disorder.

We have made great progress in our efforts to combat COVID-19 . Vaxzevria is estimated to have saved more than six million lives during the first year of roll-out, and Evusheld has protected hundreds of thousands of immunocompromised people, enabling them to return to a more normal life. Evusheld continues to demonstrate activity against new variants.

Given the ongoing performance of our underlying business and the contribution of our COVID-19 medicines, we are updating our revenue guidance for 2022. This has enabled us to increase our R&D investment in the exciting number of pipeline opportunities that can benefit patients and drive long term sustainable growth for our company. We look forward to announcing the results of several important late-stage trials this year and next ".

Would you trust AZ to tell you the truth when they knowingly kept the fatal side effects of the covid jab hidden?
25 Jul '22 - 07:07 - 5614 of 5615
0 0 0

AstraZeneca PLC said Monday that Tezspire has been recommended for approval in the EU for the treatment of severe asthma.

The pharmaceutical giant said Tezspire has been recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Asthma is a disease that affects around 14 million people living in the European Union.

Write to Kyle Morris at

(END) Dow Jones Newswires

July 25, 2022 02:44 ET (06:44 GMT)

TOP NEWS: AstraZeneca breast cancer drug wins approval in EU

Tue, 19th Jul 2022 09:22
Alliance News

(Alliance News) - AstraZeneca PLC on Tuesday said a breast cancer

drug developed with Tokyo-based partner Daiichi Sankyo Co Ltd has been approved in the European Union.

The Cambridge, England-based pharmaceutical company's Enhertu is aimed at treating those with unresectable or metastatic HER2-positive breast cancer, who have received one or more prior anti-HER2-based regimens.

HER-2 is a growth promoting protein. Unresectable tumours cannot be removed with surgery, while metastatic refers to cancer that spreads from where it started to another part of the body.

In the DESTINY-Breast03 Phase III trial, Enhertu reduced the risk of disease progression or death by 72% compared to trastuzumab emtansine. Trastuzumab emtansine is a type of targeted cancer drug for early breast cancer or breast cancer that has spread or come back within six months of finishing treatment.


Executive Vice President Dave Fredrickson said: "With this approval, patients across Europe with HER2-positive metastatic breast cancer will have the opportunity to be treated with Enhertu even earlier in the treatment of their disease, improving their chance for better outcomes beyond what we can already offer patients treated in later-line settings."

More than 530,000 patients are diagnosed with breast cancer each year, and about one in five patients are considered HER2-positive.

Following the approval by the European Commision, AstraZeneca will pay USD75 million to Daiichi Sankyo as a "milestone payment in 2nd-line HER2-positive metastatic breast cancer," the company noted.

In March 2019, Daiichi Sankyo and AstraZeneca signed a deal to develop and commercialise Enhertu.

Shares were down 0.6% at 11,033.00 pence each on Tuesday morning in London. Sankyo shares closed 2.9% lower at JPY3,508 each in Tokyo.

By Xindi Wei;

grupo guitarlumber
AstraZeneca PLC said Tuesday that its Enhertu drug has been approved in the European Union for patients with HER2-positive metastatic breast cancer .

The pharmaceutical giant said that the results of the Destiny-Breast03 study showed that Enhertu reduced the risk of disease progression or death by 72% when compared with trastuzumab emtansine.

Enhertu is jointly developed and commercialized by Astrazeneca and Daiichi Sankyo Co., the company said.

Write to Sabela Ojea at; @sabelaojeaguix

(END) Dow Jones Newswires

July 19, 2022 02:27 ET (06:27 GMT)

grupo guitarlumber
Now where the F... is Buybadly!
Now where the F... is Buybadly!
The "safe and effective" narrative is falling apart
JULY 2022
FDA and the Centers for Disease Control has compiled
- more than 1.3 million ....reports of vaccine-implicated “adverse events” running the gamut from mild to severe,

- including >>> 29,000 deaths.

In 2015, the CDC said the average number of annual reports was roughly >>> 30,000.
>>>> In 2021, there were nearly 1 million.

Jessica Rose, an independent researcher in Israel, agrees, and has devoted the past year and a half to putting VAERS under a microscope. Dr. Rose has a PhD in computational biology from Bar-Ilan University, a post-doc in molecular biology from Hebrew University, and another in biochemistry from the Technion,

In March 2022, after the COVID-19 vaccine had been available for 15 months (462 days), she compared the number of VAERS reports related ... to these covid shots
- versus those for flu vaccines.

Given the greater number of COVID shots administered during that period,
she predicted.... that “the rate of reporting in VAERS…...
- should be about.... twice for COVID.... than for flu.”

What she found instead was
>>>>> “117.6 times….. as many reports of adverse events in the context of the COVID shots.”

She said that in her analysis, >>>> 60% of VAERS reports describe events
>>> within 48 hours of vaccine administration

The last “mass vaccination program” undertaken in the United States,
- the 1976 swine flu vaccine there were approximately 55 million people vaccinated,
- with an accompanying only .... 500 cases of Guillain-Barré syndrome,
- and around 25 deaths.

“And the government officials at that time said, >>>> ‘we’re going to pull it.’”

Clot Shotts - No Doubt About It >>> it'sgenocide on a grand scale

From "covid" ........convid lol

New research - Risk From Clott Shotts >>> SIGNIFICANTLY outweighs the risk from covid itself
Peter Doshi,
>>>> a senior editor at >>>> the British Medical Journal, ...
>>> as well as physicians from UCLA.... and Stanford,
concludes that ...

- a careful analysis of all available data now suggests that the benefits of vaccination >>>> do not outweigh .....the potential harms.

To make their calculations, the researchers used data from VAERS as well as its European equivalent, EudraVigilance, and the WHO’s VigiBase.

Combined, the mRNA vaccines were associated with an absolute.... risk increase of serious adverse events of special interest of >>> 12.5X.

The excess risk of serious adverse events of special interest >>>> surpassed the risk reduction for COVID-19 hospitalization
….. relative to the placebo group in both .... Pfizer and Moderna trials

Is that the best you can do ffs ??? Duhhhhhhh !
RiskonRicky17 Jul '22 - 10:07 - 5603 of 5604
0 1 0
Nobody D-dimmer than you m8

Nobody D-dimmer than you m8
big pHARMa is a crime syndicate keeping you ill is their business

The End of Germ Theory

The jabs are poison

30.13 mins in D-Dimmer blood clot test should have been at 100-200, but came in at 7000

Those that are denying the jab is poison are to afraid to take a D-Dimmer blood test surprise there then

Waldron, yes sold GSK, got the gitters. AZN, two reasons, the buy in France and I think it's peaked for now.

I'll be back (maybe catch the divi)!

One thing weak sterling good for FTSE 100 dollar earners, when converted back to sterling for dividends.But when the market like this the good bad and ugly all get hit.Astra, GSK, Hikma, Glencore etc etc.
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older

Your Recent History

Delayed Upgrade Clock